KI
Kopp Investment Advisors LLC
13F filer · CIK 0000884306Last filed Nov 14, 2019
Inactive · not filing 13F
13F portfolio value$54.4MU.S. long equity reported on 13F
Positions390 new · 2 closed
Net flow last quarter-$23.9MBuys minus sells
Top 10 positions weight56.1%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q3 2019Reported Nov 14, 201939 positions | |||||
| $3.97M | 7.30% | 0.20% | -36.5% | Q2 2013 | |
| $3.95M | 7.25% | 0.04% | -26.7% | Q2 2014 | |
| $3.77M | 6.92% | 0.03% | -30.1% | Q4 2017 | |
| CSCYCypress Semiconductor Corp | $3.72M | 6.84% | 0.04% | -35.8% | Q1 2018 |
| $3M | 5.52% | 0.45% | -37.4% | Q1 2017 | |
| HTHZNPHorizon Therapeutics Public Ltd Co | $2.85M | 5.23% | 0.06% | -35.6% | Q2 2017 |
| $2.46M | 4.52% | 0.28% | -36.2% | Q4 2018 | |
| $2.39M | 4.38% | 0.07% | -37.1% | Q4 2018 | |
| $2.21M | 4.07% | 0.07% | -36.8% | Q2 2013 | |
| $2.19M | 4.02% | 0.22% | -34.8% | Q2 2013 | |
| $2M | 3.67% | 0.12% | -38.5% | Q3 2014 | |
| $1.36M | 2.50% | 0.09% | -36.1% | Q1 2014 | |
| $1.23M | 2.26% | Not reported | -6.7% | Q2 2013 | |
| $1.16M | 2.13% | 0.06% | -38.5% | Q2 2014 | |
| IEXENTIntersect ENT, Inc. | $1.15M | 2.11% | 0.21% | -49.3% | Q1 2015 |
| $1.05M | 1.94% | 60.23% | -25.8% | Q2 2013 | |
| $1.01M | 1.85% | 0.00% | Not reported | Q1 2015 | |
| $671K | 1.23% | 0.00% | -8.1% | Q2 2013 | |
| $647K | 1.19% | Not reported | Not reported | Q2 2018 | |
| $622K | 1.14% | 0.00% | -7.1% | Q2 2013 | |
| $608K | 1.12% | 0.00% | -7.4% | Q2 2013 | |
| $594K | 1.09% | 0.00% | -7.8% | Q3 2016 | |
| $565K | 1.04% | 0.00% | -6.4% | Q2 2013 | |
| $543K | 1.00% | 0.00% | -6.6% | Q2 2013 | |
| $538K | 0.99% | 0.00% | -7.4% | Q2 2013 | |
| $522K | 0.96% | 0.00% | -8.3% | Q1 2019 | |
| $495K | 0.91% | 0.00% | -7.3% | Q2 2013 | |
| $487K | 0.89% | 0.00% | -5.8% | Q2 2013 | |
| $479K | 0.88% | 0.00% | -6.9% | Q2 2013 | |
| $449K | 0.83% | 0.00% | -8.6% | Q1 2019 | |
| $447K | 0.82% | 0.00% | -7.7% | Q2 2013 | |
| $431K | 0.79% | 0.00% | -8.0% | Q2 2014 | |
| $379K | 0.70% | 0.00% | -8.8% | Q3 2017 | |
| $368K | 0.68% | 0.00% | -7.8% | Q3 2017 | |
| $316K | 0.58% | 0.00% | -7.2% | Q3 2017 | |
| $230K | 0.42% | 0.00% | -11.4% | Q4 2017 | |
| $218K | 0.40% | 0.00% | -6.2% | Q2 2014 | |
| $213K | 0.39% | 0.00% | -6.9% | Q3 2015 | |
| $207K | 0.38% | 0.00% | -7.8% | Q1 2019 | |
| Q2 2019Reported Aug 14, 201941 positions | |||||
| $7.18M | 8.18% | 0.32% | -17.4% | Q2 2013 | |
| $6.69M | 7.62% | 0.05% | -25.3% | Q4 2017 | |
| $5.99M | 6.82% | 0.72% | -18.9% | Q1 2017 | |
| CSCYCypress Semiconductor Corp | $5.53M | 6.30% | 0.07% | -21.3% | Q1 2018 |
| $5.04M | 5.74% | 0.44% | -19.9% | Q4 2018 | |
| $4.17M | 4.75% | 0.12% | -20.7% | Q2 2013 | |
| $4.02M | 4.58% | 0.35% | -21.7% | Q2 2013 | |
| HTHZNPHorizon Therapeutics Public Ltd Co | $3.9M | 4.44% | 0.09% | -19.9% | Q2 2017 |
| $3.9M | 4.44% | 0.05% | -10.8% | Q2 2014 | |
| $3.62M | 4.13% | 0.12% | -20.5% | Q4 2018 | |
| $3.4M | 3.88% | 0.20% | -20.1% | Q3 2014 | |
| IEXENTIntersect ENT, Inc. | $3.03M | 3.45% | 0.42% | -17.5% | Q1 2015 |
| $2.56M | 2.92% | 0.15% | -22.6% | Q1 2014 | |
| FFNSRFinisar Corp | $2.36M | 2.69% | 0.09% | -23.6% | Q2 2013 |
| $2.09M | 2.38% | 0.09% | -23.9% | Q2 2014 | |
| $1.63M | 1.85% | 73.56% | -25.7% | Q2 2013 | |
| $1.3M | 1.49% | Not reported | Not reported | Q2 2013 | |
| $889K | 1.01% | 0.00% | -38.7% | Q1 2015 | |
| $740K | 0.84% | 0.00% | -37.9% | Q2 2013 | |
| $701K | 0.80% | 0.00% | -37.0% | Q2 2013 | |
| $643K | 0.73% | 0.00% | -37.9% | Q2 2013 | |
| $640K | 0.73% | Not reported | Not reported | Q2 2018 | |
| $612K | 0.70% | 0.00% | -38.7% | Q3 2016 | |
| $606K | 0.69% | 0.00% | -39.5% | Q2 2013 | |
| $570K | 0.65% | 0.00% | -37.8% | Q2 2013 | |
| $568K | 0.65% | 0.00% | -36.4% | Q2 2013 | |
| $567K | 0.65% | 0.00% | -38.1% | Q1 2019 | |
| $563K | 0.64% | 0.00% | -36.9% | Q2 2013 | |
| $545K | 0.62% | 0.00% | -35.8% | Q2 2013 | |
| $521K | 0.59% | 0.00% | -37.7% | Q2 2013 | |
| $487K | 0.55% | 0.00% | -36.7% | Q2 2013 | |
| $487K | 0.55% | 0.00% | -41.1% | Q1 2019 | |
| $450K | 0.51% | 0.00% | -42.9% | Q2 2014 | |
| $417K | 0.48% | 0.01% | Not reported | Q1 2015 | |
| $401K | 0.46% | 0.00% | -38.7% | Q3 2017 | |
| $394K | 0.45% | 0.00% | -42.3% | Q3 2017 | |
| $357K | 0.41% | 0.00% | -37.5% | Q3 2017 | |
| $250K | 0.28% | 0.00% | -38.1% | Q4 2017 | |
| $241K | 0.27% | 0.00% | -33.6% | Q1 2019 | |
| $217K | 0.25% | 0.00% | -32.4% | Q3 2015 | |
| $216K | 0.25% | 0.00% | -27.3% | Q2 2014 | |
| Q1 2019Reported May 15, 201953 positions | |||||
| $8.48M | 6.86% | 0.07% | -2.7% | Q4 2017 | |
| $8.11M | 6.56% | 0.42% | -4.2% | Q2 2013 | |
| $6.85M | 5.54% | 0.89% | -1.6% | Q1 2017 | |
| $5.85M | 4.73% | 0.64% | +106.4% | Q4 2018 | |
| REIDTIRenesas Electronics America Inc. | $5.42M | 4.38% | 0.09% | -9.7% | Q2 2013 |
| HTHZNPHorizon Therapeutics Public Ltd Co | $5.35M | 4.33% | 0.11% | +38.4% | Q2 2017 |
| IEXENTIntersect ENT, Inc. | $5.18M | 4.19% | 0.52% | -0.3% | Q1 2015 |
| $4.94M | 3.99% | 0.15% | -1.5% | Q2 2013 | |
| CSCYCypress Semiconductor Corp | $4.71M | 3.81% | 0.09% | +5.4% | Q1 2018 |
| $4.69M | 3.80% | 0.15% | +97.3% | Q4 2018 | |
| $4.64M | 3.75% | 0.26% | +44.4% | Q3 2014 | |
| $4.61M | 3.73% | 0.44% | +20.4% | Q2 2013 | |
| CCLDRCloudera, Inc. | $4.32M | 3.49% | 0.15% | New | Q1 2019 |
| $3.59M | 2.90% | 0.12% | -0.9% | Q2 2014 | |
| $3.5M | 2.83% | 0.19% | +31.6% | Q1 2014 | |
| $3.48M | 2.81% | 0.06% | -1.4% | Q2 2014 | |
| FFNSRFinisar Corp | $3.14M | 2.54% | 0.11% | -2.2% | Q2 2013 |
| $2.41M | 1.95% | 97.59% | -0.8% | Q2 2013 | |
| $1.39M | 1.13% | 0.00% | -1.7% | Q1 2015 | |
| $1.26M | 1.02% | Not reported | Not reported | Q2 2013 | |
| $1.06M | 0.86% | 0.00% | -9.3% | Q2 2013 | |
| $1.02M | 0.82% | 0.00% | -0.9% | Q2 2013 | |
| $1.02M | 0.82% | 0.00% | -0.8% | Q2 2013 | |
| $982K | 0.79% | 0.00% | +21.6% | Q2 2013 | |
| $913K | 0.74% | 0.00% | -1.9% | Q2 2013 | |
| $911K | 0.74% | 0.00% | -1.0% | Q2 2013 | |
| $904K | 0.73% | 0.00% | -1.2% | Q3 2016 | |
| $887K | 0.72% | 0.00% | +0.2% | Q2 2013 | |
| $865K | 0.70% | 0.00% | New | Q1 2019 | |
| $840K | 0.68% | 0.00% | -1.4% | Q2 2013 | |
| $821K | 0.66% | 0.00% | -2.8% | Q2 2013 | |
| $820K | 0.66% | 0.00% | New | Q1 2019 | |
| $796K | 0.64% | 0.00% | +0.4% | Q2 2013 | |
| $719K | 0.58% | 0.00% | +2.6% | Q2 2014 | |
| $687K | 0.56% | 0.00% | -0.2% | Q3 2017 | |
| $648K | 0.52% | 0.00% | -1.9% | Q3 2017 | |
| $615K | 0.50% | Not reported | +3.0% | Q2 2018 | |
| $566K | 0.46% | 0.00% | +7.4% | Q3 2017 | |
| $397K | 0.32% | 0.01% | Not reported | Q1 2015 | |
| $356K | 0.29% | 0.00% | -5.6% | Q4 2017 | |
| $333K | 0.27% | 0.00% | Not reported | Q2 2014 | |
| CCELGCelgene Corp | $323K | 0.26% | 0.00% | -2.4% | Q3 2017 |
| $294K | 0.24% | 0.00% | +4.8% | Q2 2013 | |
| $291K | 0.24% | 0.00% | Not reported | Q1 2018 | |
| $288K | 0.23% | Not reported | New | Q1 2019 | |
| $285K | 0.23% | 0.00% | Not reported | Q3 2015 | |
| $273K | 0.22% | 0.00% | +0.2% | Q3 2018 | |
| $242K | 0.20% | 0.00% | +0.3% | Q2 2013 | |
| $238K | 0.19% | 0.00% | Not reported | Q3 2018 | |
| $236K | 0.19% | 0.00% | Not reported | Q4 2018 | |
| Q4 2018Reported Feb 14, 201954 positions | |||||
| $6.91M | 6.74% | 0.91% | -0.7% | Q1 2017 | |
| $6.03M | 5.88% | 0.07% | -1.0% | Q4 2017 | |
| REIDTIRenesas Electronics America Inc. | $5.93M | 5.78% | 0.09% | -1.7% | Q2 2013 |
| $5.22M | 5.09% | 0.44% | -0.3% | Q2 2013 | |
| IEXENTIntersect ENT, Inc. | $4.55M | 4.44% | 0.53% | -13.4% | Q1 2015 |
| $4.37M | 4.26% | 0.37% | -1.0% | Q2 2013 | |
| IIMPVImperva Inc | $4.2M | 4.10% | 0.21% | -0.6% | Q4 2016 |
| CSCYCypress Semiconductor Corp | $3.81M | 3.72% | 0.08% | -7.1% | Q1 2018 |
| $3.8M | 3.70% | 0.15% | -0.4% | Q2 2013 | |
| $3.31M | 3.23% | 0.12% | -1.0% | Q2 2014 | |
| FFNSRFinisar Corp | $2.99M | 2.92% | 0.12% | -0.5% | Q2 2013 |
| $2.94M | 2.87% | 0.06% | +0.1% | Q2 2014 | |
| HTHZNPHorizon Therapeutics Public Ltd Co | $2.86M | 2.79% | 0.09% | +58.8% | Q2 2017 |
| NMNXTMNxStage Medical, Inc. | $2.79M | 2.72% | 0.15% | -1.4% | Q4 2013 |
| $2.62M | 2.56% | 0.09% | -0.7% | Q2 2013 | |
| $2.52M | 2.46% | 0.15% | +82.2% | Q1 2014 | |
| $2.22M | 2.16% | 0.18% | -3.0% | Q3 2014 | |
| $1.97M | 1.92% | 0.08% | New | Q4 2018 | |
| $1.82M | 1.77% | 0.31% | New | Q4 2018 | |
| $1.18M | 1.15% | 0.00% | +0.9% | Q1 2015 | |
| $1.11M | 1.08% | Not reported | Not reported | Q2 2013 | |
| $1.02M | 0.99% | 0.00% | -4.2% | Q2 2013 | |
| $941K | 0.92% | 0.00% | -0.4% | Q2 2013 | |
| $933K | 0.91% | 0.00% | +1.9% | Q2 2013 | |
| $882K | 0.86% | 0.00% | -1.3% | Q3 2016 | |
| $844K | 0.82% | Not reported | -14.9% | Q4 2015 | |
| $833K | 0.81% | 0.00% | -4.6% | Q2 2013 | |
| $786K | 0.77% | 0.00% | -0.3% | Q2 2013 | |
| $772K | 0.75% | 0.00% | -2.7% | Q2 2013 | |
| $756K | 0.74% | 0.00% | -0.3% | Q2 2013 | |
| $753K | 0.73% | 0.00% | +3.0% | Q2 2013 | |
| $741K | 0.72% | Not reported | -1.1% | Q1 2015 | |
| $715K | 0.70% | 0.00% | -1.5% | Q2 2013 | |
| $714K | 0.70% | 0.00% | +0.2% | Q2 2013 | |
| $646K | 0.63% | 0.00% | -2.2% | Q2 2014 | |
| $608K | 0.59% | 0.00% | +1.4% | Q1 2016 | |
| $599K | 0.58% | 0.00% | -2.6% | Q2 2013 | |
| $584K | 0.57% | 0.00% | +0.7% | Q3 2017 | |
| $579K | 0.56% | 0.00% | +2.7% | Q3 2017 | |
| $513K | 0.50% | Not reported | Not reported | Q2 2018 | |
| $466K | 0.45% | 0.00% | -0.4% | Q3 2017 | |
| $430K | 0.42% | Not reported | -0.3% | Q2 2013 | |
| $325K | 0.32% | 0.00% | +14.4% | Q4 2017 | |
| $307K | 0.30% | 0.00% | +14.9% | Q4 2017 | |
| $291K | 0.28% | 0.00% | +11.0% | Q2 2014 | |
| $289K | 0.28% | 0.00% | +13.8% | Q2 2013 | |
| $289K | 0.28% | 0.01% | Not reported | Q1 2015 | |
| $260K | 0.25% | 0.00% | +14.7% | Q2 2013 | |
| $247K | 0.24% | 0.00% | Not reported | Q3 2015 | |
| $236K | 0.23% | 0.00% | +18.3% | Q3 2018 | |
Premium opens every quarter this fund has filed